Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
- PMID: 33676597
- PMCID: PMC7972318
- DOI: 10.1016/S0140-6736(21)00461-X
Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
Abstract
Background: Azithromycin, an antibiotic with potential antiviral and anti-inflammatory properties, has been used to treat COVID-19, but evidence from community randomised trials is lacking. We aimed to assess the effectiveness of azithromycin to treat suspected COVID-19 among people in the community who had an increased risk of complications.
Methods: In this UK-based, primary care, open-label, multi-arm, adaptive platform randomised trial of interventions against COVID-19 in people at increased risk of an adverse clinical course (PRINCIPLE), we randomly assigned people aged 65 years and older, or 50 years and older with at least one comorbidity, who had been unwell for 14 days or less with suspected COVID-19, to usual care plus azithromycin 500 mg daily for three days, usual care plus other interventions, or usual care alone. The trial had two coprimary endpoints measured within 28 days from randomisation: time to first self-reported recovery, analysed using a Bayesian piecewise exponential, and hospital admission or death related to COVID-19, analysed using a Bayesian logistic regression model. Eligible participants with outcome data were included in the primary analysis, and those who received the allocated treatment were included in the safety analysis. The trial is registered with ISRCTN, ISRCTN86534580.
Findings: The first participant was recruited to PRINCIPLE on April 2, 2020. The azithromycin group enrolled participants between May 22 and Nov 30, 2020, by which time 2265 participants had been randomly assigned, 540 to azithromycin plus usual care, 875 to usual care alone, and 850 to other interventions. 2120 (94%) of 2265 participants provided follow-up data and were included in the Bayesian primary analysis, 500 participants in the azithromycin plus usual care group, 823 in the usual care alone group, and 797 in other intervention groups. 402 (80%) of 500 participants in the azithromycin plus usual care group and 631 (77%) of 823 participants in the usual care alone group reported feeling recovered within 28 days. We found little evidence of a meaningful benefit in the azithromycin plus usual care group in time to first reported recovery versus usual care alone (hazard ratio 1·08, 95% Bayesian credibility interval [BCI] 0·95 to 1·23), equating to an estimated benefit in median time to first recovery of 0·94 days (95% BCI -0·56 to 2·43). The probability that there was a clinically meaningful benefit of at least 1·5 days in time to recovery was 0·23. 16 (3%) of 500 participants in the azithromycin plus usual care group and 28 (3%) of 823 participants in the usual care alone group were hospitalised (absolute benefit in percentage 0·3%, 95% BCI -1·7 to 2·2). There were no deaths in either study group. Safety outcomes were similar in both groups. Two (1%) of 455 participants in the azothromycin plus usual care group and four (1%) of 668 participants in the usual care alone group reported admission to hospital during the trial, not related to COVID-19.
Interpretation: Our findings do not justify the routine use of azithromycin for reducing time to recovery or risk of hospitalisation for people with suspected COVID-19 in the community. These findings have important antibiotic stewardship implications during this pandemic, as inappropriate use of antibiotics leads to increased antimicrobial resistance, and there is evidence that azithromycin use increased during the pandemic in the UK.
Funding: UK Research and Innovation and UK Department of Health and Social Care.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7975322/bin/gr1.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7975322/bin/gr2.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7975322/bin/gr3.gif)
Comment in
-
COVID-19, community trials, and inclusion.Lancet. 2021 Mar 20;397(10279):1036-1037. doi: 10.1016/S0140-6736(21)00661-9. Lancet. 2021. PMID: 33743853 Free PMC article. No abstract available.
Similar articles
-
Antibiotics for the treatment of COVID-19.Cochrane Database Syst Rev. 2021 Oct 22;10(10):CD015025. doi: 10.1002/14651858.CD015025. Cochrane Database Syst Rev. 2021. PMID: 34679203 Free PMC article. Review.
-
Systemic corticosteroids for the treatment of COVID-19.Cochrane Database Syst Rev. 2021 Aug 16;8(8):CD014963. doi: 10.1002/14651858.CD014963. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 Nov 17;11:CD014963. doi: 10.1002/14651858.CD014963.pub2. PMID: 34396514 Free PMC article. Updated. Review.
-
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.Lancet. 2021 Sep 4;398(10303):843-855. doi: 10.1016/S0140-6736(21)01744-X. Epub 2021 Aug 10. Lancet. 2021. PMID: 34388395 Free PMC article. Clinical Trial.
-
Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.Lancet Respir Med. 2021 Sep;9(9):1010-1020. doi: 10.1016/S2213-2600(21)00310-6. Epub 2021 Jul 27. Lancet Respir Med. 2021. PMID: 34329624 Free PMC article. Clinical Trial.
-
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.Lancet. 2021 Feb 13;397(10274):605-612. doi: 10.1016/S0140-6736(21)00149-5. Epub 2021 Feb 2. Lancet. 2021. PMID: 33545096 Free PMC article. Clinical Trial.
Cited by
-
Community antibiotic prescribing in patients with COVID-19 across three pandemic waves: a population-based study in Scotland, UK.BMJ Open. 2024 Apr 19;14(4):e081930. doi: 10.1136/bmjopen-2023-081930. BMJ Open. 2024. PMID: 38643000 Free PMC article.
-
Exploring factors shaping antibiotic resistance patterns in Streptococcus pneumoniae during the 2020 COVID-19 pandemic.Elife. 2024 Mar 7;13:e85701. doi: 10.7554/eLife.85701. Elife. 2024. PMID: 38451256 Free PMC article.
-
Ivermectin for COVID-19 in adults in the community (PRINCIPLE): An open, randomised, controlled, adaptive platform trial of short- and longer-term outcomes.J Infect. 2024 Apr;88(4):106130. doi: 10.1016/j.jinf.2024.106130. Epub 2024 Feb 29. J Infect. 2024. PMID: 38431155 Free PMC article. Clinical Trial.
-
Hospital Antibiotic Consumption before and during the COVID-19 Pandemic in Hungary.Antibiotics (Basel). 2024 Jan 20;13(1):102. doi: 10.3390/antibiotics13010102. Antibiotics (Basel). 2024. PMID: 38275331 Free PMC article.
-
Democratising the design and delivery of large-scale randomised, controlled clinical trials in primary care: A personal view.Eur J Gen Pract. 2024 Dec;30(1):2293702. doi: 10.1080/13814788.2023.2293702. Epub 2024 Jan 5. Eur J Gen Pract. 2024. PMID: 38180050 Free PMC article.
References
-
- Kim PS, Read SW, Fauci AS. Therapy for early COVID-19: a critical need. JAMA. 2020;324:2149–2150. - PubMed
-
- Poschet J, Perkett E, Timmins G, Deretic V. Azithromycin and ciprofloxacin have a chloroquine-like effect on respiratory epithelial cells. bioRxiv. 2020 doi: 10.1101/2020.03.29.008631. published online March 31. (preprint). - DOI
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous